COMMUNIQUÉS West-GlobeNewswire
-
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
22/05/2026 -
Cartigenix HP® Backed by Three Human Studies as Clinicians Seek Evidence-Based Joint Health Options
22/05/2026 -
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
22/05/2026 -
SBC Medical and BLEZ ASIA Celebrate Opening of New Aesthetic Dermatology Section at BLEZ CLINIC in Bangkok
22/05/2026 -
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
22/05/2026 -
BioAge Labs to Present at Upcoming Investor Conferences
22/05/2026 -
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
22/05/2026 -
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
22/05/2026 -
CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU
22/05/2026 -
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
22/05/2026 -
Ebola Outbreak “Spreading at Alarming Speed,” WHO Warns — Growing Global Health Emergencies Highlight Rising Need for TOMI’s SteraMist Technology
22/05/2026 -
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
22/05/2026 -
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
22/05/2026 -
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
22/05/2026 -
American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on June 24, 2026
22/05/2026 -
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
22/05/2026 -
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
22/05/2026 -
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
22/05/2026 -
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
22/05/2026
Pages